CIK 0001680581 · Non-accelerated filer<br>Smaller reporting company
Fulcrum Therapeutics, Inc.
Sign in to watch- Ticker
- FULC
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 474839948
- Phone
- 617-651-8851
- Business address
- 26 LANDSDOWNE STREET, CAMBRIDGE, MA, 02139
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 83 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-02-02 | Sapir Alex See Remarks | Grant or award · Stock option - Right to Buy | +650,000 | 650,000 | ||
| 2026-01-02 | Gould Robert J Director | Sale | −15,000 | $10.87 | $163K | 469,864 |
| 2026-01-02 | Gould Robert J Director | Sale | −15,000 | $11.87 | $178K | 469,864 |
| 2025-12-15 | Oltmans Curtis Gale Chief Legal Officer | Sale | −3,452 | $12.92 | $45K | 10,252 |
| 2025-12-08 | RA CAPITAL MANAGEMENT, L.P. 10% owner | Sale | −1,377,020 | $13.33 | $18.4M | 8,852,079 |
| 2025-12-08 | RA CAPITAL MANAGEMENT, L.P. 10% owner | Sale | −2,706,397 | $14.28 | $38.6M | 6,145,682 |
| 2025-12-08 | RA CAPITAL MANAGEMENT, L.P. 10% owner | Sale | −91,722 | $14.98 | $1.4M | 6,053,960 |
| 2025-11-19 | Gould Robert J Director | Sale | −15,000 | $11.03 | $165K | 484,864 |
| 2025-06-26 | King Rachel K. Director | Grant or award · Stock Option (right to buy) | +36,000 | 36,000 | ||
| 2025-06-26 | GERAGHTY JAMES A Director | Grant or award · Stock Option (right to buy) | +36,000 | 36,000 | ||
| 2025-06-26 | Dorton Katina Director | Grant or award · Stock Option (right to buy) | +36,000 | 36,000 | ||
| 2025-06-26 | Haviland Kate Director | Grant or award · Stock Option (right to buy) | +36,000 | 36,000 | ||
| 2025-06-26 | Hill Colin Director | Grant or award · Stock Option (right to buy) | +36,000 | 36,000 | ||
| 2025-06-26 | Banks Sonja Director | Grant or award · Stock Option (right to buy) | +36,000 | 36,000 | ||
| 2025-06-26 | Gould Robert J Director | Grant or award · Stock Option (right to buy) | +36,000 | 36,000 | ||
| 2025-06-26 | Ezekowitz Alan Director | Grant or award · Stock Option (right to buy) | +36,000 | 36,000 | ||
| 2025-05-08 | Tourangeau Greg Principal Accounting Officer | Sale | −498 | $5.06 | $3K | 14,062 |
| 2025-01-24 | Musso Alan A Chief Financial Officer | Grant or award · Stock Option (right to buy) | +285,000 | 285,000 | ||
| 2025-01-24 | Sapir Alex See Remarks | Grant or award · Stock option - Right to Buy | +582,000 | 582,000 | ||
| 2025-01-24 | Tourangeau Greg Principal Accounting Officer | Grant or award · Stock Option (right to buy) | +76,120 | 76,120 |
Page 2 of 7 · 136 trades